Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on November 3, 2021, to report its third-quarter 2021 financial and operating results. The company announced its Q3 2021 earnings, providing key financial metrics and operational updates. Investors should refer to the press release furnished as Exhibit 99.1 for detailed information regarding these results. The filing itself is primarily procedural, incorporating the press release which contains the substantive financial and operational data. This press release details the company's performance during the quarter ended September 30, 2021, and is the primary source of information for understanding Regeneron's recent financial standing and business developments.
Key Highlights
- 1Regeneron announced its financial and operating results for the third quarter ended September 30, 2021.
- 2The Q3 2021 results were disclosed via a press release furnished as an exhibit to the 8-K filing.
- 3The filing does not contain new financial statements or detailed operational data directly, but incorporates by reference the press release (Exhibit 99.1).
- 4Information furnished under Item 2.02 and Exhibit 99.1 is generally not considered 'filed' for Section 18 purposes unless specifically incorporated into other filings.
- 5Investors are directed to the press release for comprehensive details on the company's performance during the period.
- 6The 8-K serves as the formal notification of the earnings release and the availability of the results.